Home » Vanda Announces Positive Results in the Second Phase III Study of Tasimelteon
Vanda Announces Positive Results in the Second Phase III Study of Tasimelteon
Vanda Pharmaceuticals announced positive results for the second Phase III study of tasimelteon for the treatment of Non-24-Hour Disorder.
Benzinga
Benzinga
Upcoming Events
-
07May
-
14May
-
30May